PMID: 26793881Jan 23, 2016Paper

The mechanism of progression without androgen receptor interaction in prostate cancer

Nihon rinsho. Japanese journal of clinical medicine
Hideyasu Matsuyama, Hiroaki Matsumoto

Abstract

Recently, new generation androgen receptor (AK) targeted agents enzautamide or abiraterone etc.) has been clinically utilized in patients with castration-resistant prostate cancer (CRPC). However, metastatic CRPC has also AR-independent survival pathway which leads to lethal phenotype by either adaptation or clonal selection resistant mechanism after AR targeted therapy. There are many studies regarding the progression mechanisms without AR signal transduction, such as growth factor, anti-apoptotic factor, and PTEN/mTOR pathway and so on. Also, cancer microenvironment and cancer stem cell is a hot research area for CRPC. It is very important to repress both AR-dependent and -independent signaling pathway to improve the clinical outcome in CRPC patients. Application of the new technology, such as next generation sequencing, would be developing for the prostate cancer research, providing pre-clinical proof-of-principle as a promising approach in CRPC.

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Related Papers

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutica
F RecineF Calabrò
Expert Opinion on Pharmacotherapy
Charles J Ryan, Michael L Cheng
Nihon rinsho. Japanese journal of clinical medicine
Seiji Naito, Masaki Shiota
© 2022 Meta ULC. All rights reserved